Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy

Tumor Biology ◽  
2015 ◽  
Vol 37 (2) ◽  
pp. 1753-1762 ◽  
Author(s):  
Rujiao Liu ◽  
Xiaoying Zhao ◽  
Xin Liu ◽  
Zhiyu Chen ◽  
Lixin Qiu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Mthfr Polymorphisms ◽  
Gastric Cancer Patients

scholarly journals Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients

2021 ◽  
Vol 10 (1) ◽  
pp. 1915560
Author(s):  
Kaifeng Jin ◽  
Yifan Cao ◽  
Yun Gu ◽  
Hanji Fang ◽  
Yuchao Fei ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
T Cells ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Cd8 T Cells ◽  
Gastric Cancer Patients

scholarly journals Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel

Oncotarget ◽  
2018 ◽  
Vol 9 (20) ◽  
pp. 15219-15227 ◽  
Author(s):  
Naoki Fukuda ◽  
Daisuke Takahari ◽  
Takeru Wakatsuki ◽  
Hiroki Osumi ◽  
Izuma Nakayama ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Gastric Cancer Patients

MET amplification occurrence and prediction of unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15047-e15047 ◽  
Author(s):  
Yu-hong Li ◽  
Xin An ◽  
Fang Wang ◽  
Qiong Shao ◽  
Feng-Hua Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Protein Expression ◽  
Cancer Patients ◽  
Clinical Outcomes ◽  
Performance Status ◽  
Progression Free Survival ◽  
Metastatic Gastric Cancer ◽  
Poor Performance Status ◽  
Met Amplification ◽  
Gastric Cancer Patients

e15047 Background: Several large studies have reported an extremely low incidence of MET gene amplification (GA) in patients with radically resected gastric cancer. The aim of our study was to evaluate the prevalence and prognostic role of MET GA and protein expression in recurrent/metastatic gastric cancer patients who received chemotherapy. Methods: This retrospective study included 232 recurrent/metastatic gastric cancer patients. MET GA and protein expression were evaluated by fluorescent in-situ hybridization (FISH) and immunohistochemistry (IHC), respectively.Results: MET GA and strong protein expression were observed in 8.3% and 9.6% of patients, respectively. MET IHC 3+ was significantly correlated with GA. Patients with MET GA more frequently had a poor performance status (P < 0.001) and poorly differentiate tumors (P = 0.015) than those without MET GA. Both MET GA and IHC 3+ expression were associated with substantially shorter median progression free survival (PFS) and overall survival (OS). The median OS and PFS for patients with MET GA positive vs. MET GA negative were 5.7 vs. 15.5 months (P < 0.001) and 3.6 vs. 6.9 months (P < 0.001), respectively.The median OS and PFS for patients with MET IHC 3+ vs. IHC (0 to 2+) were 6.3 vs. 15.1 months (P < 0.001) and 3.6 vs. 7.0 months (P < 0.001), respectively. Conclusions: In recurrent/metastatic gastric cancer, MET amplification and strong protein expression are not rare and significantly associated with unfavorable clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document